Company news
Hoth Therapeutics, Inc. news in 2020
Hoth Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment
December 30, 2020
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients
December 22, 2020
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
December 9, 2020
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
November 2, 2020
Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine
November 1, 2020
Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic
October 19, 2020
Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)
September 23, 2020
Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go COVID-19 Testing Device
September 20, 2020
Hoth Therapeutics Appoints Stefanie Johns, Ph.D., as Chief Scientific Officer
August 30, 2020
Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in September
August 27, 2020
Hoth Therapeutics Provides Shareholder Update on COVID-19 Initiatives and Dermatological Therapy Pipeline
August 18, 2020
Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis
August 12, 2020
Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device
August 9, 2020
Hoth Therapeutics Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological Diseases
July 30, 2020
Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment
June 29, 2020
Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University for Dermatology Treatment Candidate WEG232
June 15, 2020
Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions
June 7, 2020
Hoth Therapeutics Announces Closing of Public Offering of Common Stock
May 26, 2020
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board
May 21, 2020
Hoth Announces Pricing of Public Offering of Shares of Common Stock
May 20, 2020
Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic
May 19, 2020
Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.
May 4, 2020
Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study
April 20, 2020
Hoth Therapeutics Announces Additions to its Board of Directors
April 16, 2020
Hoth Therapeutics Commences Next Phase of VNLG-152 Study
April 8, 2020
Hoth Update on HaloVax Partnership Vaccine to Fight COVID-19 with Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH)
April 1, 2020
Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals, Inc. to License VNLG-152 for Treatment of Dermatological Diseases
March 29, 2020
Hoth Announces Pricing of $5 Million Public Offering of Common Stock
March 23, 2020
Hoth Therapeutics Announces Agreement to Joint Development of a Self-Assembling Vaccine (SAV) for the Potential Treatment of the Coronavirus (COVID-19)
March 22, 2020
Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss
March 18, 2020
Hoth Therapeutics Receives Notice of Allowance from European Patent Office
February 18, 2020
Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
February 11, 2020
Hoth Initiates Preclinical Gene Therapy Program with NC State for the Treatment of Asthma and Allergic Inflammation
February 3, 2020
Hoth Therapeutics to Further its Research of VNLG-152 and Plans Exercise of its Option Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.
January 28, 2020
Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis
January 20, 2020
Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects
January 14, 2020